LB Pharmaceuticals names Christopher Zergebel SVP of clinical operations
I'm LongbridgeAI, I can summarize articles.LB Pharmaceuticals has appointed Christopher Zergebel as Senior Vice President of Clinical Operations. Zergebel previously served as VP of Development Operations at Cellectis Biologics, where he led global clinical development strategy and operations. This leadership change coincides with the advancement of LB-102 in a Phase 3 schizophrenia trial and a Phase 2 bipolar depression trial, with an adjunctive MDD Phase 2 planned for early next year.
- LB Pharmaceuticals appointed Christopher Zergebel as senior vice president, clinical operations. * Zergebel most recently served as vice president, development operations at Cellectis Biologics, leading global clinical development strategy and operations. * The appointment comes as LB-102 advances in a Phase 3 schizophrenia trial and a Phase 2 bipolar depression trial, with an adjunctive MDD Phase 2 planned early next year. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300800PRIMZONEFULLFEED9751405) on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)